Clinical Trials Logo

Clinical Trial Summary

A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.


Clinical Trial Description

This is a Phase 1, first-in-human, open-label, single-arm study in which adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie are treated with autologous plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system (ISP-001). This study will evaluate the safety and tolerability of ISP-001. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05682144
Study type Interventional
Source Immusoft of CA, Inc.
Contact Jake Wesley, PharmD, MS
Email jake.wesley@immusoft.com
Status Recruiting
Phase Phase 1
Start date April 12, 2023
Completion date June 1, 2039